Reduction of intramyocellular lipid following short-term rosiglitazone treatment in zucker fatty rats: An in vivo nuclear magnetic resonance study

Metabolism: Clinical and Experimental

Volumn 52, Issue 2, 2003, Pages 218-225

  Jucker, Beat M ^a   Schaeffer, Thomas R ^a   Haimbach, Robin E ^a   Mayer, Matthew E ^a   Ohlstein, Derek H ^a   Smith, Stephen A ^a   Cobitz, Alexander R ^a   Sarkar, Susanta K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN SENSITIZING AGENT; LIPID; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WATER; CELL LEVEL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID STORAGE; LIPOLYSIS; LONG TERM CARE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RAT; RAT STRAIN; SHORT COURSE THERAPY; TIBIALIS ANTERIOR MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037303806     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2003.50040     Document Type: Article

References (44)

1. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 38:1595-1607, 1988
2. Kolterman OG, Gray RS, Griffin J, et al: Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 68:957-969, 1981
3. Kolterman OG, Reaven GM, Olefsky JM: Relationship between in vivo insulin resistance and decreased insulin receptors in obese man. J Clin Endocrinol Metab 48:487-494, 1979
4. Yki-Jarvinen H, Kiovisto VA: Effects of body composition on insulin sensitivity. Diabetes 32:965-969, 1983
5. Dresner A, Laurent D, Marcucci M, et al: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999
6. Griffin ME, Marcucci MJ, Cline GW, et al: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
7. Montell E, Turini M, Marotta M, et al; DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab 280:E229-237, 2001
8. Idris I, Gray S, Donnelly R: Protein kinase C activation: Isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44:659-673, 2001
9. Beck-Nielsen H: Mechanisms of insulin resistance in non-oxidative glucose metabolism: The role of glycogen synthase. J Basic Clin Physiol Pharmacol 9:225-279, 1998
10. Randle PJ, Garland PB, Hales CN, et al: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789, 1963
11. Roden M, Price TB, Perseghin G, et al: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865, 1996
12. 13C nuclear magnetic resonance study. Diabetes 48:134-140, 1999
13. Storlien LH, Jenkins AB, Chisholm DJ, et al: Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 40:280-289, 1991
14. Kraegen EW, Clark PW, Jenkins AB, et al: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397-1403, 1991
15. Ye J-M, Doyle PJ, Iglesias MA, et al: Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison With PPAR-γ activation. Diabetes 50:411-417, 2001
16. Oakes ND, Camilleri S, Furler SM, et a; The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 46:935-942, 1997
17. Schick F, Eismann B, Jung WI, et al: Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: Two lipid compartments in muscle tissue. Magn Reson Med 29:158-167, 1993
18. 1H NMR spectroscopy study. Diabetologia 42:113-116, 1999
19. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50:2337-2343, 2001
20. Jacob S, Machann J, Pett K, et al: Association of increased intramyocellular lipid content with insulin resistant in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48:1113-1119, 1999
21. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600-1606, 1999
22. Bachamann OP, Dahl DB, Brechtel K, et al: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50:2579-2584, 2001
23. 1H-MRS study. Magn Reson Med 45:179-183, 2001
24. Boden G, Lebed B, Schatz M, et al: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612-1617, 2001
25. Oakes ND, Kennedy CJ, Jenkins AB, et al: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
26. Young PW, Cathorne MA, Coyle PJ, et al: Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44:1087-1092, 1995
27. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109, 1996
28. Kanoh Y, Bandyopadhyay G, Sajan MP, et al: Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats. Endocrinology 142:1595-1605, 2001
29. Yonemitsu S, Nishimura H, Shintani M, et al: Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50:1093-1101, 2001
30. Oakes ND, Thalen PG, Jacinto SM, et al: Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158-1165, 2001
31. Boesch C, Slotboom J, Hoppeler H, et al: In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 37:484-493, 1997
32. Frayn KN, Maycock PF: Skeletal muscle triacylglycerol in the rat: Methods for sampling and measurement, and studies of biological variability. J Lipid Res 21:139-144, 1980
33. DeFronzo RA, Jacot E, Jequier E, et al: The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007, 1981
34. Pan DA, Lillioja S, Kriketos AD, et al: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988, 1997
35. Young PW, Buckle DR, Cantello BC, et al: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284:751-759, 1998
36. Schmitz-Peiffer C, Browne CL, Oakes ND, et al: Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46:169-178, 1997
37. Chao L, Marcus-Samuels B, Mason MM, et al: Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228, 2000
38. Burant CF, Sreenan S, Hirano K, et al: Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908, 1997
39. Sreenan S, Keck S, Fuller T, et al: Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 276:E1119-E1129, 1999
40. Mayerson AB, Hundal RS, Dufour S, et al: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
41. Decombaz J, Schmitt B, Ith M, et al: Postexercise fat intake repletes intramyocellular lipids but no faster in trained than in sedentary subjects. Am J Physiol 281:R760-R769, 2001
42. Hwang J-H, Pan JW, Heydari S, et al: Regional differences in intramyocellular lipids in humans observed by in vivo 1H-MR spectroscopic imaging. J Appl Physiol 90:1267-1274, 2001
43. Sinha R, Dufour S, Petersen KF, et al: Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: Relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022-1027, 2002
44. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994